HRMY - Harmony Biosciences Holdings - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4131971040
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. Web URL: https://www.harmonybiosciences.com
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
HRMY Stock Overview
| Market Cap in USD | 2,134m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Pharmaceuticals |
| TER | 0.00% |
| IPO / Inception | 2020-08-19 |
HRMY Stock Ratings
| Growth 5y | -0.68 |
| Fundamental | 78.6 |
| Dividend | 0.00 |
| Rel. Performance vs Sector | 0.66 |
| Analysts | 3.86/5 |
| Fair Price Momentum | 35.55 USD |
| Fair Price DCF | 91.01 USD |
HRMY Dividends
| Dividend Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
HRMY Growth Ratios
| Growth 12m | 6.76% |
| Growth Correlation 12m | 57% |
| Growth Correlation 3m | 82% |
| CAGR 5y | -1.61% |
| CAGR/Mean DD 5y | -0.05 |
| Sharpe Ratio 12m | 0.04 |
| Alpha vs SP500 12m | -36.62 |
| Beta vs SP500 5y weekly | 1.27 |
| ValueRay RSI | 9.49 |
| Volatility GJR Garch 1y | 57.61% |
| Price / SMA 50 | -4% |
| Price / SMA 200 | 6.36% |
| Current Volume | 387.4k |
| Average Volume 20d | 572.4k |
External Links for HRMY Stock
News
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
What is the price of HRMY stocks?
As of October 06, 2024, the stock is trading at USD 34.60 with a total of 387,445 shares traded.
Over the past week, the price has changed by -11.58%, over one month by -4.00%, over three months by +8.87% and over the past year by +6.15%.
As of October 06, 2024, the stock is trading at USD 34.60 with a total of 387,445 shares traded.
Over the past week, the price has changed by -11.58%, over one month by -4.00%, over three months by +8.87% and over the past year by +6.15%.
What are the forecast for HRMY stock price target?
According to ValueRays Forecast Model, HRMY Harmony Biosciences Holdings will be worth about 39.5 in October 2025. The stock is currently trading at 34.60. This means that the stock has a potential upside of +14.19%.
According to ValueRays Forecast Model, HRMY Harmony Biosciences Holdings will be worth about 39.5 in October 2025. The stock is currently trading at 34.60. This means that the stock has a potential upside of +14.19%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 43.3 | 25.1 |
| Analysts Target Price | 42.9 | 24.0 |
| ValueRay Target Price | 39.5 | 14.2 |